ImmunityBio (IBRX) stock fell 7.25% to $9.27 despite ANKTIVA trial results showing a 71% response rate and lasting benefits ...
Short-Course Radiotherapy Supports Organ Preservation in Locally Advanced Rectal Cancer / locally advanced rectal cancer, ...
Global survey explores whether maintenance HER2-targeted therapy can be stopped after prolonged remission in HER2-positive ...
A new PET imaging approach detected 97.9% of lesions in clear cell renal cell carcinoma (ccRCC), potentially giving ...
Patient’s Skin Improved from Severe to Clear with Complete Elimination of Pruritus (itch) – After 21 Months of Treatment with ...
GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as ...
Objectives Tuberculosis (TB) in the USA disproportionately affects non-US-born individuals. While testing this population for ...
Femasys is a commercial-stage medtech company targeting OB/GYNs with in-office fertility and permanent birth control ...
A cross-sectional survey of 345 licensed Saudi community pharmacists mapped self-reported medication-adherence strategies, ...
The novel oral helicase-primase inhibitor offers a non-intravenous option for immunocompromised adults with mucocutaneous HSV refractory to standard antivirals.
The US Food and Drug Administration (FDA) has approved pritelivir (HOVILPRI; Asahi Kasei Therapeutics) 100-mg tablets for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results